Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience, Inc. (VIGL) is a pioneering biopharmaceutical company dedicated to developing microglia-focused therapeutics. These specialized treatments aim to treat both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain’s immune system. Vigil Neuroscience leverages modern neuroscience drug development tools to create precision-based therapies that significantly improve the quality of life for patients and their families.
One of the company's key initiatives is the clinical development of iluzanebart, which is currently in a Phase 2 Proof of Concept (PoC) trial named IGNITE. This is the first-ever interventional trial targeting Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) patients, marking a critical advancement in the treatment landscape for this rare disease. In addition, the company is working on VG-3927, an orally available small molecule TREM2 agonist designed to treat more common neurodegenerative diseases associated with microglial dysfunction.
Vigil Neuroscience has also made notable strides in community engagement and support. Their comprehensive patient support initiatives include the ALSPAware program, which offers no-cost genetic testing and counseling. This program aims to reduce the barriers to accurate diagnosis and enable better disease management for ALSP patients.
Recent research presented by the company has revealed significant findings on the diagnostic challenges faced by the ALSP community. For instance, a retrospective analysis disclosed that only 24.7 percent of ALSP patients received an accurate initial diagnosis, with many being misdiagnosed with multiple sclerosis (MS) due to similar early symptoms. Vigil Neuroscience's ongoing research aims to provide better diagnostic tools and treatment options, thereby improving the overall patient journey.
Additionally, Vigil Neuroscience has been actively presenting its latest findings and achievements at various conferences. Recent presentations have highlighted the potential of VG-3927 to treat neurodegenerative diseases like Alzheimer's Disease (AD), showcasing its neuroprotective profile and ability to favorably modulate microglia activation.
As Vigil Neuroscience continues to advance its clinical programs and expand its therapeutic pipeline, it remains committed to delivering innovative solutions that address the unmet needs of patients suffering from neurodegenerative diseases.
Vigil Neuroscience (Nasdaq: VIGL) announced upcoming presentations at three investor conferences. The events include a fireside chat at Guggenheim's 4th Annual Immunology and Neurology Day on November 14, 2022, at 1:35 p.m. ET, followed by a chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 8:35 a.m. ET, and finally, a presentation at the Jefferies London Healthcare Conference on November 16, 2022, at 2:05 p.m. GMT. Live webcasts can be accessed on their website, and archived replays will be available for 90 days.
Vigil focuses on microglia for treating neurodegenerative diseases.
Vigil Neuroscience (VIGL) reported interim topline results from its Phase 1 clinical trial of VGL101 in healthy volunteers, establishing a foundation for a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). VGL101 demonstrated favorable safety and tolerability, with a robust reduction in cerebrospinal fluid (CSF) sTREM2 levels, indicating effective target engagement. The company is set to initiate the Phase 2 trial with a 20 mg/kg dosage this quarter, representing a significant milestone for the ALSP community.
Vigil Neuroscience (Nasdaq: VIGL) has received FDA Fast Track designation for its lead product candidate, VGL101, aimed at treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). This designation highlights the unmet medical needs of approximately 10,000 ALSP patients in the U.S. VGL101 is a TREM2 agonist currently undergoing a Phase 1 trial in healthy volunteers. The company aims to report Phase 1 topline data and initiate a Phase 2 proof-of-concept trial for VGL101 this quarter.
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotechnology firm, will participate in a fireside chat at the 2022 Morgan Stanley Global Healthcare Conference on September 12, 2022, at 4:50 p.m. ET. The event aims to showcase their focus on harnessing microglia for treating neurodegenerative diseases. Investors can access the live webcast through the company’s website in the 'Investors' section, with an archived replay available for 90 days post-event.
Vigil Neuroscience specializes in developing therapies to restore microglial function, addressing both rare and common diseases.
Vigil Neuroscience (Nasdaq: VIGL) announced a private investment in public equity (PIPE) financing, raising approximately $75 million by issuing 7,293,084 shares at $7.30 each and Pre-Funded Warrants for 2,980,889 shares at $7.2999. The financing is expected to close on August 16, 2022. Proceeds will support clinical development of TREM2 agonist therapies for neurodegenerative diseases. With this funding, Vigil anticipates operational plans to extend into Q1 2025. The investment was led by Deep Track Capital and included various other investors.
Vigil Neuroscience, a clinical-stage biotechnology firm (Nasdaq: VIGL), announced its participation in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022, at 11:30 a.m. ET. The management team will engage in a fireside chat to discuss the company’s focus on microglia-targeted therapies for neurodegenerative diseases. Investors can access the live webcast through the ‘Events & Presentations’ section of Vigil's website, with an archived replay available for 90 days after the event.
The company aims to restore microglial function to develop precision-based treatments.
Vigil Neuroscience (Nasdaq: VIGL) recently presented findings at the Alzheimer's Association International Conference. Their lead product candidate, VGL101, showed promise in treating Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP). The study revealed VGL101's ability to rescue microglial dysfunction in preclinical models. A systematic review indicated a mean age of onset for ALSP symptoms at 43.2 years. The company emphasizes the importance of genetic testing due to frequent misdiagnoses as other neurodegenerative diseases.
Vigil Neuroscience (Nasdaq: VIGL) has appointed Suzanne Bruhn, Ph.D., to its Board of Directors, enhancing its leadership with over 20 years of biopharmaceutical experience. Dr. Bruhn's expertise in rare diseases and neuroscience is seen as an asset for Vigil’s mission to develop microglia-targeted therapies for neurodegenerative conditions. Notably, she has held significant roles in successful organizations, including Tiaki Therapeutics and Proclara Biosciences. This leadership change is expected to bolster Vigil's strategic direction in drug development, although it also introduces potential risks associated with transitioning leadership.
Vigil Neuroscience has received approval from the Human Research Ethics Committee in Australia to conduct a Phase 1 trial of VGL101 in healthy volunteers, allowing doses above 20 mg/kg. The FDA has also suggested considering a 30 mg/kg dose for the U.S. trial. Vigil is on track to report topline data from this trial and initiate a Phase 2 trial for ALSP in Q4 2022. The company emphasizes the favorable safety and pharmacokinetic profile of VGL101, aimed at treating neurodegenerative diseases, specifically ALSP.
Vigil Neuroscience, Inc. (Nasdaq: VIGL) has announced that CEO Ivana Magovčević-Liebisch, Ph.D., J.D., will speak at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 2:00 p.m. ET in New York City. The event will focus on the company's commitment to leveraging microglia to develop therapies for neurodegenerative diseases. A live webcast of the discussion can be accessed through the 'Investors' section of their website, with an archived replay available for 90 days post-event.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
What is the primary focus of Vigil Neuroscience, Inc.?
What is iluzanebart?
What is VG-3927?
What is the ALSPAware program?
What recent findings has Vigil Neuroscience presented?
How does Vigil Neuroscience contribute to the neurodegenerative disease community?
What is the IGNITE trial?
Why is microglia important in neurodegenerative diseases?
What challenges do ALSP patients face in terms of diagnosis?
Who can I contact for investor and media inquiries?
